Key points are not available for this paper at this time.
This Viewpoint discusses the US Food and Drug Administration’s upcoming mandate on diversity actions plans for trial sponsors and the importance of developing accountability mechanisms to monitor those plans.
Metcalfe et al. (Fri,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: